Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT
Table 2. Effect of HCQ+AZ on outpatient mortality—multivariable logistic regression (n = 2015 patients 60 years).
OR 95% CI p
Age (ref. 60–69 years)
70–79 2.81 0.88–8.96 0.0802
>79 8.29 2.52–27.20 0.0005
Sex (ref. women)
Men 3.61 1.29–10.07 0.0145
Epidemic period (ref. period 1)
Period 2 0.14 0.01–2.58 0.1856
Period 3 0.58 0.17–1.93 0.3743
Treatment (ref. no dual therapy)
HCQ+AZ 0.17 0.06–0.48 0.0007
OR, odds ratio; CI, confidence interval; Ref, reference; AZ, azithromycin; HCQ, hydroxychloroquine.
The two-way interaction between treatment and age was not statistically significant (p = 0.57).